The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 26, Issue 6, Pages 1195-1202
Publisher
Springer Nature
Online
2011-12-06
DOI
10.1038/leu.2011.339
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT
- (2011) Bernhard Svejda et al. CANCER
- Targeting translation in acute myeloid leukemia: A new paradigm for therapy?
- (2011) Jerome Tamburini et al. CELL CYCLE
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
- (2010) Patrizia Sini et al. Autophagy
- The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
- (2010) A. S. Green et al. BLOOD
- Targeting autophagy to fight hematopoietic malignancies
- (2010) Alexandre Puissant et al. CELL CYCLE
- Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
- (2010) N. Chapuis et al. CLINICAL CANCER RESEARCH
- Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
- (2010) N Chapuis et al. LEUKEMIA
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Taking aim at protein translation in AML
- (2009) M. Carroll BLOOD
- Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
- (2009) J. Tamburini et al. BLOOD
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
- (2009) S. Assouline et al. BLOOD
- TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
- (2009) J. Copp et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
- (2009) A. E. Perl et al. CLINICAL CANCER RESEARCH
- mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action
- (2009) Ghada A. Soliman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation